KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Impact of Ecological Momentary Assessment Participation on Short-Term Smoking Cessation: quitSTART Ecological Momentary Assessment Incentivization Randomized Trial. PMID 40680166 · J Med Internet Res · 2025-Jul-18 The study is a randomized controlled trial in humans, but it is not an oncology trial (smoking cessation), does not involve a drug intervention, and does not use a time-to-event endpoint (primary outcome is abstinence at fixed time points, not a survival or time-to-event analysis).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intraoperative parathyroid hormone monitoring to guide surgery in renal hyperparathyroidism (PEREGRINE): a protocol for a randomised multiarm surgical pilot trial. PMID 40675640 · BMJ Open · 2025-Jul-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Indocyanine green fluorescence in pelvic lymph node dissection during laparoscopic radical prostatectomy: a randomized controlled trial. PMID 40670731 · Updates Surg · 2025-Jul-16 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081. PMID 40664454 · J Immunother Cancer · 2025-Jul-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Effect of Forgiveness Psychoeducation on Forgiveness, Self-Compassion and Death Anxiety in Cancer Patients: A Randomized Controlled Trial. PMID 40663159 · Omega (Westport) · 2025-Jul-15 The record reports a randomized controlled trial in oncology patients, but it tests a non-drug intervention (forgiveness psychoeducation) and its endpoints are psychological outcomes, not time-to-event efficacy measures. Therefore, it does not meet the criteria for inclusion in the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Perioperative administration of CBM588 in colorectal cancer radical surgery: A single-center, randomized controlled trial. PMID 40633539 · Cell Rep Med · 2025-Jul-15 The study is a Phase IV randomized controlled trial in colorectal cancer with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The endpoints are postoperative functional recovery and immune status, not survival or progression-based outcomes. Therefore, it is ineligible for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study. PMID 40450840 · J Neurol Sci · 2025-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial. PMID 40079683 · Int J Cancer · 2025-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast cancer survivors (PACHA): protocol for a pilot cluster-randomized controlled trial. PMID 40660375 · Pilot Feasibility Stud · 2025-Jul-14 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A Personalized, Texting-Based Conversational Agent to Address Sleep Disturbance in Individuals Who Have Survived Breast Cancer: Protocol for a Pilot Waitlist Randomized Controlled Trial. PMID 40658949 · JMIR Res Protoc · 2025-Jul-14 This is a protocol for a pilot randomized trial of a non-drug, digital cognitive behavioral therapy intervention for sleep disturbance in breast cancer survivors. It is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention, does not report efficacy results, and has no time-to-event primary or key secondary endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Influence of different photobiomodulation protocols on the prevention of chemotherapy-induced dysgeusia in breast cancer patients treated with Doxorubicin-Cyclophosphamide: a phase III, randomized, triple-blinded non-inferiority clinical trial. PMID 40658227 · Support Care Cancer · 2025-Jul-14 The record is a Phase III randomized trial in oncology with a drug intervention, but it does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The endpoints are toxicity, quality of life, and other non-survival outcomes.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Surgery or radiotherapy for early-stage cancer study (SORT) target trial protocol: stereotactic ablative radiotherapy (SABR) with curative intent versus surgical resection for early-stage non-small cell lung cancer (NSCLC). PMID 40659399 · BMJ Open · 2025-Jul-13 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of proactively inviting people with advanced cancer to talk about the end of life: a randomised clinical trial protocol. PMID 40659391 · BMJ Open · 2025-Jul-13 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers. PMID 40652143 · J Cancer Res Clin Oncol · 2025-Jul-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
STUDY PROTOCOL FOR A DUAL-CENTER RANDOMIZED CONTROLLED TRIAL COMPARING LAPAROSCOPIC AND OPEN 'MINOR' LIVER RESECTIONS IN UKRAINIAN COLORECTAL CANCER PATIENTS WITH LIVER METASTASES. PMID 40674155 · Exp Oncol · 2025-Jul-11 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Artificial capnothorax versus single-lung ventilation in minimally invasive esophagectomy for esophageal cancer: A randomized controlled trial. PMID 40640078 · Chin Med J (Engl) · 2025-Jul-10 The study is a randomized oncology trial with time-to-event efficacy results, but it lacks a drug-containing intervention, which is a required criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study. PMID 40639850 · J Immunother Cancer · 2025-Jul-10 The report is an original result of a randomized, human oncology trial with a drug intervention and time-to-event efficacy endpoints. However, it is explicitly described as a 'pilot study', which is generally considered an early-phase (e.g., Phase II) or feasibility study, not a definitive Phase III/IIIb or Phase II/III trial. The instructions exclude early-phase studies and require explicit establishment of Phase III/IIIb or Phase II/III status, which is not met here.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Theory-based chatbot for promoting colorectal cancer screening in a community setting in Hong Kong: study protocol of a randomised controlled trial. PMID 40639841 · BMJ Open · 2025-Jul-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Early-life undernutrition increases the risk of death from chronic diseases in adulthood: a population-based cohort study. PMID 40635115 · Glob Health Res Policy · 2025-Jul-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. PMID 40626388 · Cochrane Database Syst Rev · 2025-Jul-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer: The REAL Randomized Clinical Trial. PMID 40455621 · JAMA · 2025-Jul-08 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Endobiliary radiofrequency ablation in recurrence and unresectable Perihilar cholangiocarcinoma. PMID 40619373 · BMC Gastroenterol · 2025-Jul-07 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Impact of RoSCo-based preoperative risk stratification on early mobilization and short-term outcomes following robot-assisted laparoscopic partial nephrectomy for renal cell carcinoma: a single-center prospective study. PMID 40619492 · J Robot Surg · 2025-Jul-06 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Effect of astaxanthin supplementation on cycling performance, muscle damage biomarkers and oxidative stress in young adults: a randomized controlled trial. PMID 40615903 · BMC Sports Sci Med Rehabil · 2025-Jul-04 This is a randomized controlled trial in healthy young adults evaluating astaxanthin supplementation for exercise performance and muscle damage. It is not an oncology study, does not involve human malignant neoplasms, does not report a time-to-event cancer efficacy endpoint (OS, PFS, DFS, etc.), and the intervention is a dietary supplement, not a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study. PMID 40592718 · Oncologist · 2025-Jul-04 Metadata confirms oncology, human, randomized, drug intervention, time-to-event endpoint, and original result. However, the required 'Phase III/IIIb or Phase II/III' evidence is not explicitly established in the title, abstract, or metadata, leaving 'phase3_or_definitive' as null. Without explicit confirmation of the definitive phase, eligibility cannot be set to true.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER). PMID 40591514 · Oncologist · 2025-Jul-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer. PMID 40554667 · Oncologist · 2025-Jul-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Supporting patients with advanced cancer and their spouses in parenting minor children: results of a randomized controlled trial. PMID 39703166 · Oncologist · 2025-Jul-04 The study is an oncology randomized controlled trial, but it is a psychosocial intervention trial without a drug intervention and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Induction chemotherapy plus chemoradiotherapy in esophageal cancer: long-term results and exploratory analyses of a randomized controlled trial. PMID 39584557 · Oncologist · 2025-Jul-04 The report is an oncology, human, randomized trial with a drug intervention and primary time-to-event efficacy endpoints (OS, PFS) presented as long-term final results. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata or abstract, so eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial. PMID 39475418 · Oncologist · 2025-Jul-04 The study is excluded because it is not a randomized controlled trial. It is an observational, real-world cohort study, which does not meet the requirement for a randomized Phase III/IIIb or Phase II/III trial. While it is an oncology study with a drug intervention and reports time-to-event efficacy results, the lack of randomization and interventional trial phase makes it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol. PMID 40615151 · BMJ Open · 2025-Jul-03 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial. PMID 39841461 · Blood · 2025-Jul-03 The abstract reports on an induction phase analysis of a Phase III trial with a drug-containing regimen, but it does not report a primary or key secondary time-to-event efficacy endpoint. It focuses on response rates, MRD negativity, safety, and stem cell collection. The study is ongoing with continued follow-up required. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase-II randomized study of carboplatin plus capecitabine versus 3-weekly cisplatin in locally advanced head-and-neck cancer patients undergoing concurrent chemoradiation (CARCAP-HN). PMID 41004292 · J Cancer Res Ther · 2025-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Modified Target Delineation and Moderately Hypofractionated Radiotherapy for High-Grade Glioma: A Randomized Clinical Trial. PMID 40705330 · JAMA Netw Open · 2025-Jul-01 The record describes a randomized clinical trial with drug intervention (temozolomide) and time-to-event endpoints (PFS, OS) in oncology, but the trial phase is not explicitly established as Phase III/IIIb or Phase II/III. The 'deterministic_review' signals 'phase3_evidence_unclear', and no publication type or text explicitly confirms a definitive phase. Therefore, the criterion for phase is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Homelessness, Patient Navigation, and Lung Cancer Screening in a Health Center Setting: A Subgroup Analysis of a Randomized Clinical Trial. PMID 40674053 · JAMA Netw Open · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of 12-Week Dietary Inflammatory Index-Based Dietary Education on Frailty Status in Frail Patients with Colorectal Cancer: A Randomized Controlled Trial. PMID 40647307 · Nutrients · 2025-Jul-01 The study is a randomized controlled trial in oncology (colorectal cancer) with a primary result, but it fails two key eligibility criteria: (1) the intervention is a non-drug dietary education program, not a drug-containing intervention; (2) the primary outcomes are frailty phenotype, inflammatory biomarkers, nutritional status, and quality of life, not a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term implant survival in delayed breast reconstruction. PMID 40613789 · BJS Open · 2025-Jul-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
The effect of qigong on frailty in older cancer survivors: a randomised controlled trial. PMID 40613666 · Age Ageing · 2025-Jul-01 The study is a randomized controlled trial in human cancer survivors, meeting oncology and randomization criteria. However, it is excluded because it does not involve a drug-containing intervention (qigong vs. light exercise) and does not use a time-to-event efficacy endpoint (primary outcome is frailty reversal, a categorical binary outcome).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison between mixed reality with artificial algorithms and ultrasound in localization of anterior thigh flap perforators: a prospective randomized controlled study. PMID 40598466 · BMC Med · 2025-Jul-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Impact of the 5A nursing model on immune balance and lymph node metastasis in primary liver cancer patients post-CyberKnife treatment. PMID 40597871 · BMC Cancer · 2025-Jul-01 Excluded because the intervention is non-drug (nursing model + radiotherapy) and the trial phase is not confirmed as definitive (Phase III/IIIb or II/III).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma. PMID 40595067 · Sci Rep · 2025-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma. PMID 40595001 · Sci Rep · 2025-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial. PMID 40593475 · Nat Commun · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study. PMID 40593014 · Sci Rep · 2025-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Quality comparison of mediastinal lymph node dissection between video-assisted thoracic surgery and open thoracotomy: a supplementary analysis of the phase 3 Japan Clinical Oncology Group 1413 trial†. PMID 40578313 · Eur J Cardiothorac Surg · 2025-Jul-01 The report is a secondary analysis of a Phase III RCT comparing surgical techniques, not a drug intervention. The primary endpoint is N2 upstaging, a categorical pathological endpoint, not a time-to-event efficacy endpoint (OS, PFS, etc.). Therefore, it does not meet the core criteria for inclusion in this oncology KM digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of definitive uterine artery occlusion on ovarian reserve markers in laparoscopic myomectomy: a randomized controlled trial with 2-year follow-up. PMID 40420404 · Hum Reprod · 2025-Jul-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial. PMID 40372727 · JAMA Oncol · 2025-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study. PMID 40300087 · Clin Cancer Res · 2025-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial. PMID 40260648 · Clin Cancer Res · 2025-Jul-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program. PMID 40243198 · Cancer Prev Res (Phila) · 2025-Jul-01 While the study meets several criteria (randomized, phase III, human, time-to-event endpoint), it is excluded because it is not a therapeutic trial for an existing malignant neoplasm. It is a cancer prevention trial in a diabetes population, and the intervention is not a drug-containing regimen for treating diagnosed cancer.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -